These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1350482)

  • 21. The once-daily dose regimen of carvedilol: a meta-analysis approach.
    Stienen U
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S128-33. PubMed ID: 1378140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial.
    Takeda T; Kohno M; Ishii M; Kubo S; Saruta T; Mizuno Y; Fukiyama K; Fujishima M; Yoshimura M
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S158-63. PubMed ID: 1974508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
    Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
    J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension.
    Eggertsen R; Sivertsson R; Andrén L; Hansson L
    J Hypertens; 1984 Oct; 2(5):529-34. PubMed ID: 6152280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of carvedilol on left ventricular function and mass in hypertension.
    Why HJ; Richardson PJ
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S50-4. PubMed ID: 1378151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.
    Tham TC; Guy S; McDermott BJ; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1995 Jul; 40(1):19-23. PubMed ID: 8527263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group.
    Young PH
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S82-5. PubMed ID: 1378155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure.
    Franz IW; Agrawal B; Wiewel D; Ketelhut R
    Clin Investig; 1992; 70 Suppl 1():S53-7. PubMed ID: 1350485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of salt intake on the antihypertensive effect of carvedilol.
    Ruilope LM; Lahera V
    J Hypertens Suppl; 1993 Jun; 11(4):S17-9. PubMed ID: 8104238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carvedilol prevents severe hypertensive cardiomyopathy and remodeling.
    Barone FC; Campbell WG; Nelson AH; Feuerstein GZ
    J Hypertens; 1998 Jun; 16(6):871-84. PubMed ID: 9663928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of 2 beta-receptor blocking agents on the microcirculation of healthy subjects and of hypertensive patients.
    Albrecht M; Haustein KO
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):580-6. PubMed ID: 9455718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.
    Flack JM
    J Clin Hypertens (Greenwich); 2010 Sep; 12(9):664-5. PubMed ID: 20928961
    [No Abstract]   [Full Text] [Related]  

  • 33. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol.
    Si D; Wang J; Xu Y; Chen X; Zhang M; Zhou H
    J Cardiovasc Pharmacol; 2014 Oct; 64(4):306-9. PubMed ID: 25291495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension.
    Juttmann JR; de Vries Robles P; Venuti RP
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S134-7. PubMed ID: 1378141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of carvedilol in older and younger patients.
    Morgan T; Anderson A; Cripps J; Adam W
    J Hum Hypertens; 1990 Dec; 4(6):709-15. PubMed ID: 2096213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects.
    Cournot A; Lim C; Duchier J; Safar M
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S35-9. PubMed ID: 1378147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects.
    Lehtonen L; Sundberg S
    Eur J Clin Pharmacol; 2002 Oct; 58(7):449-52. PubMed ID: 12389066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy of carvedilol in severe hypertension.
    Ogihara T; Yoshinaga K; Kamahara Y; Ikeda M; Goto Y; Arakawa K; Iimura I; Ishii M; Kokubu T; Takeda T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S69-72. PubMed ID: 1721983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carvedilol in the treatment of mild to moderate hypertension: experience with ambulatory blood pressure monitoring.
    Biston P; Van de Borne P; Mélot C; Smekens P; Marinus W; Degaute JP
    Acta Cardiol; 1994; 49(2):145-55. PubMed ID: 8053282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension.
    Bakris GL; Weber MA
    Rev Cardiovasc Med; 2008; 9(2):96-105. PubMed ID: 18660730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.